Altimmune (ALT) Other Accumulated Expenses (2014 - 2026)
Altimmune (ALT) reported Other Accumulated Expenses of $313000.0 for Q1 2026, up 458.93% year-over-year from $56000.0 in Q1 2025, and down 0.63% quarter-over-quarter from $315000.0 in Q4 2025.
Altimmune (ALT) Other Accumulated Expenses (2014 - 2026) Analysis & Trends
Altimmune (ALT) has 9 years of Other Accumulated Expenses data on file, last reported at $313000.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $313000.0, up 458.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $313000.0 (up 458.93% YoY), and the FY2025 annual result was $315000.0, up 472.73% from the prior year.
- Other Accumulated Expenses retreated to $313000.0 in Q1 2026 per ALT's latest filing, from $315000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $315000.0 in Q4 2025 and troughed at $54000.0 in Q3 2024.
- A 5-year average of $137727.3 and a median of $103000.0 in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses sank 55.65% in 2024, then surged 472.73% in 2025.
- A 5-year view of Other Accumulated Expenses shows it stood at $103000.0 in 2022, then gained by 20.39% to $124000.0 in 2023, then slumped by 55.65% to $55000.0 in 2024, then surged by 472.73% to $315000.0 in 2025, then retreated by 0.63% to $313000.0 in 2026.
- Business Quant data shows ALT's Other Accumulated Expenses at $313000.0 in Q1 2026, $315000.0 in Q4 2025, and $177000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 313,000.00 |
| Dec 31, 2025 | 315,000.00 |
| Sep 30, 2025 | 177,000.00 |
| Jun 30, 2025 | 183,000.00 |
| Mar 31, 2025 | 56,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 54,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Dec 31, 2023 | 124,000.00 |
| Dec 31, 2022 | 103,000.00 |
| Mar 31, 2017 | 11,588.00 |
| Dec 31, 2016 | 11,588.00 |
| Sep 30, 2016 | 11,588.00 |
| Jun 30, 2016 | 11,588.00 |
| Dec 31, 2015 | 11,250.00 |
| Jun 30, 2015 | 74,233.00 |
| Mar 31, 2015 | 72,674.00 |
| Dec 31, 2014 | 70,326.00 |